Receptor News and Research

RSS

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Researchers at NYU Grossman School of Medicine in New York have conducted a study demonstrating the effectiveness of the Pfizer-BioNtech BNT162b2 vaccine against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Feb 2021

MSK researchers report an underlying cause of COVID brain

One of the dozens of unusual symptoms that have emerged in COVID-19 patients is a condition that's informally called "COVID brain" or "brain fog."

9 Feb 2021

New drug shows promise in treating pancreatic and breast cancers

ProAgio, a drug developed by Georgia State University biology professor Zhi-Ren Liu and his team, is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular and Molecular Gastroenterology and Hepatology.

9 Feb 2021

New combination treatment approach improves overall survival in mice with glioblastoma

In a study of mice, researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new approach that combines an anti-psychotic drug, a statin used to lower high cholesterol levels, and radiation to improve the overall survival in mice with glioblastoma.

9 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

COVID-19 vaccination associated with 3- to 5-fold reduction in viral load

Researchers in Israel report a reduction in viral load in vaccinated individuals.

9 Feb 2021

Study reveals new molecular mechanism linked to severe anaphylaxis

Anaphylaxis is a systemic allergic reaction that can affect the skin, the gastrointestinal tract, the respiratory system and the cardiovascular system.

9 Feb 2021

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

A new study provides direct evidence that the oligosaccharides attached to the viral surface spike protein are essential for viral infection, offering new approaches to preventive and therapeutic drugs.

9 Feb 2021

Subgenomic RNAs could help identify asymptomatic SARS-CoV-2 infection

Researchers report the association of subgenomic RNA (sgRNA) production, the structural differences between sgRNA variants, and clinical severity in 81 clinical specimens obtained from both asymptomatic and symptomatic individuals with SARS-CoV-2 infection.

9 Feb 2021

Emergence and transmission of UK SARS-CoV-2 variant in the US

Researchers describe the impending rise to dominance of the B.1.1.7 (UK) variant in the US. Understanding this development will help to shape preventive action to reduce the infection and mortality rates.

9 Feb 2021

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A new study describes the first case of anti-SARS-CoV-2 antibodies detected in the cord blood of an infant born to a mother immunized with the first dose of an mRNA COVID-19 vaccine three weeks earlier.

9 Feb 2021

Pancreatic β cells secrete miR-29 in response to high levels of free fatty acids

In a new study published in Journal of Extracellular Vesicles, Chen-Yu Zhang's group and Antonio Vidal-Puig's group at University of Cambridge report that pancreatic β cells secrete miR-29 family members (miR-29a, miR-29b and miR-29c) in response to high levels of free fatty acids (FFAs). These β cell-derived miR-29s are delivered to the liver, promoting insulin resistance and enhancing hepatic glucose output.

9 Feb 2021

Pfizer-BioNTech COVID-19 vaccine immune response in the elderly

In a recent medRxiv preprint publication, the team led by Professor Ravindra K. Gupta has assessed the real-world immune responses following the vaccination against the SARS-CoV-2. The team measured 1) IFN-gamma (interferon-gamma) T cell responses, 2) both total IgG Spike/ IgG Spike RBD (receptor binding domain) and 3) neutralizing antibody responses to Spike in sera.

8 Feb 2021

Researchers find new clues to how SARS-CoV-2 infects cells

The molecular details of how SARS-CoV-2 enters cells and infects them are still not clear. Researchers at Uppsala University have tested the bioinformatic predictions made by another research group and have identified receptors that could be important players in the process.

8 Feb 2021

4th preclinical study for Novavax in non-human primates, tests SARS-CoV-2 variants

Researchers in the United States have identified specific immune correlates that might be key to ensuring that vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protects against not only disease, but also viral transmission and emerging variants.

8 Feb 2021

Moderna's COVID-19 vaccine effective against emerging variants

Researchers have conducted a study showing that the Moderna mRNA-1273 vaccine effectively protects against recently emerged variants of SARS-CoV-2 – the agent that causes COVID-19.

8 Feb 2021

Scientists produce active antigen in bacteria to help combat SARS-CoV-2

Researchers at the University of Nebraska Medical Center have developed a bacterial strategy for the expression and purification of the SARS-CoV-2 spike protein receptor-binding domain (RBD).

8 Feb 2021

Furin cleavage SARS-CoV-2 spike deletions mostly suppressed within infected airway epithelium, says study

A team of researchers recently examined the SARS-CoV-2 transcriptome and the dynamics of the S gene furin cleavage site in primary human airway epithelia.

8 Feb 2021

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

A new study describes the use of DARPin (designed ankyrin repeat proteins) therapeutic agents, each of which contains three different DARPin domains within the same molecule.

8 Feb 2021

Could graphene be an effective antiviral platform against SARS-CoV-2?

The urgent need for novel therapeutics has spurred investigation into broad-spectrum inhibitors of viral infection and replication. A new study describes the antiviral activity of synthesized graphene platforms, pointing to new therapeutic approaches against this virus.

8 Feb 2021